The AKT1 Knockout 786-O Polyclonal Cells comprise a pool of 786-O cells subjected to CRISPR/Cas9-mediated disruption of the AKT1 locus, generating a heterogeneous population of AKT1-null and edited cells suitable for loss-of-function studies. This polyclonal format avoids clonal artifacts and provides a representative knockout model without single-cell cloning, enabling robust investigation of AKT1-dependent signaling in a renal carcinoma context.
The parental 786-O cell line is a human clear cell renal cell carcinoma (ccRCC) epithelial model derived from a primary clear cell adenocarcinoma. These cells are VHL-deficient, leading to constitutive stabilization of hypoxia-inducible factor (HIF) transcription factors and upregulation of HIF targets, recapitulating a hallmark molecular feature of ccRCC.
AKT1 is a serine/threonine kinase that functions as a central mediator of the PI3K signaling cascade. Upon receptor tyrosine kinase activation, AKT1 is recruited to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) at the plasma membrane and activated by PDK1-mediated phosphorylation at Thr308 and mTORC2-mediated phosphorylation at Ser473. Active AKT1 phosphorylates a diverse set of substrates, including GSK3?? (inhibition), FOXO1/3a (nuclear exclusion and inhibition), TSC2 (inhibition), PRAS40 (inhibition), and BAD (inhibition), thereby driving cell survival, proliferation, metabolism, and angiogenesis. By inhibiting TSC2 and PRAS40, AKT1 relieves repression of mTORC1, resulting in phosphorylation of S6K1 and 4E-BP1 and increased cap-dependent translation. Negative regulation is provided by PTEN, which dephosphorylates PIP3, and PHLPP, which directly dephosphorylates AKT1 at Ser473. AKT1 also forms complexes with chaperones HSP90 and CDC37, and adaptor APPL1, which regulate its stability and signaling specificity.
In the context of 786-O cells, which lack functional VHL and exhibit constitutive HIF transcriptional activity, AKT1 integrates metabolic and growth cues. AKT1 knockout disrupts the PI3K/AKT/mTOR signaling axis, leading to diminished phosphorylation of GSK3?? and FOXO factors, and likely derepression of pro-apoptotic BAD and activation of FOXO target genes. The subsequent attenuation of mTORC1 activity via TSC2 and PRAS40 reduces protein synthesis and cell growth, making this polyclonal knockout a valuable tool for examining AKT1-dependent oncogenic mechanisms and for assessing sensitivity to AKT inhibitors in a VHL-null background.
Researchers can employ this pool to investigate AKT1 function in RCC proliferation, apoptosis, migration, and metabolism using MTT, colony formation, Annexin V, Transwell, and metabolic flux assays. Western blotting for phospho-AKT (Ser473/Thr308), phospho-GSK3??, and phospho-S6 confirms knockout effects. The model is suited for AKT inhibitor pharmacodynamics (e.g., MK-2206, ipatasertib) and VHL/HIF-PI3K crosstalk studies. Additional applications include FOXO immunofluorescence and flow cytometry. For technical inquiries, contact Ascent Research.
